- Home
- GOF vs VRDN Comparison
GOF vs VRDN Comparison
Compare GOF & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOF
- VRDN
- Stock Information
- Founded
- GOF 2006
- VRDN 2006
- Country
- GOF United States
- VRDN United States
- Employees
- GOF N/A
- VRDN N/A
- Industry
- GOF Finance/Investors Services
- VRDN Medical Specialities
- Sector
- GOF Finance
- VRDN Health Care
- Exchange
- GOF Nasdaq
- VRDN Nasdaq
- Market Cap
- GOF 2.3B
- VRDN 2.1B
- IPO Year
- GOF N/A
- VRDN N/A
- Fundamental
- Price
- GOF $13.05
- VRDN $28.78
- Analyst Decision
- GOF
- VRDN Strong Buy
- Analyst Count
- GOF 0
- VRDN 11
- Target Price
- GOF N/A
- VRDN $39.60
- AVG Volume (30 Days)
- GOF 789.2K
- VRDN 1.9M
- Earning Date
- GOF 01-01-0001
- VRDN 11-05-2025
- Dividend Yield
- GOF 15.42%
- VRDN N/A
- EPS Growth
- GOF N/A
- VRDN N/A
- EPS
- GOF N/A
- VRDN N/A
- Revenue
- GOF N/A
- VRDN $70,789,000.00
- Revenue This Year
- GOF N/A
- VRDN N/A
- Revenue Next Year
- GOF N/A
- VRDN $37,670.06
- P/E Ratio
- GOF N/A
- VRDN N/A
- Revenue Growth
- GOF N/A
- VRDN 23340.07
- 52 Week Low
- GOF $10.96
- VRDN $9.90
- 52 Week High
- GOF $16.76
- VRDN $29.00
- Technical
- Relative Strength Index (RSI)
- GOF 37.82
- VRDN 74.87
- Support Level
- GOF $13.12
- VRDN $22.14
- Resistance Level
- GOF $13.35
- VRDN $28.60
- Average True Range (ATR)
- GOF 0.33
- VRDN 1.27
- MACD
- GOF 0.04
- VRDN 0.47
- Stochastic Oscillator
- GOF 16.39
- VRDN 91.63
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).